<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="949">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307693</url>
  </required_header>
  <id_info>
    <org_study_id>S2020-0472-0001</org_study_id>
    <nct_id>NCT04307693</nct_id>
  </id_info>
  <brief_title>Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</brief_title>
  <official_title>Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral
      activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there
      is no clinical studies on the reduction of viral load in patients with COVID-19. This study
      investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from
      respiratory specimen in patients with mild COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study is an open-labelled, randomized clinical trial for 1:1:1 ratio of
      lopinavir/ritonavir, hydroxychloroquine, or control arm.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early because no patients were further enrolled since mid-Apr 2020.
  </why_stopped>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, open labelled, randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load</measure>
    <time_frame>hospital day 3, 5, 7, 10, 14, 18</time_frame>
    <description>Area under the curve (AUC) of Ct value or viral copies number per mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load change</measure>
    <time_frame>hospital day 3, 5, 7, 10, 14, 18</time_frame>
    <description>Viral load change (log10 viral load assessed by reverse transcription-PCR) during hospital day 3, 5, 7, 10, 14, 18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement (TTCI)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Time to clinical improvement (TTCI) is defined as the time to normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough within at least 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of progression to supplemental oxygen requirement by day 7</measure>
    <time_frame>hospital day 7</time_frame>
    <description>Percentage of progression to supplemental oxygen requirement by day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7</measure>
    <time_frame>hospital day 7</time_frame>
    <description>Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7</measure>
    <time_frame>hospital day 7</time_frame>
    <description>Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Safety and tolerability, as assessed by adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Lopinavir/ritonavir and hydroxychloroquine</measure>
    <time_frame>1, 2, 4, 5, 12 hours after taking intervention medicine</time_frame>
    <description>Concentration of Lopinavir/ritonavir and hydroxychloroquine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No lopinavir/ritonavir and hydroxychloroquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Lopinavir / Ritonavir tablet</description>
    <arm_group_label>Lopinavir/ritonavir</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine sulfate</intervention_name>
    <description>Hydroxychloroquine sulfate tablet</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Oxiklorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed mild COVID-19 (NEWS scoring system 0-4)

        Exclusion Criteria:

          -  unable to take oral medication

          -  pregnancy or breast feeding

          -  immunocompromised patients

          -  creatinine clearance (CCL) &lt; 30 mL/min

          -  aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 5 times Upper limit of
             normal (ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Han Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

